Form 4: Entera Bio Grants Equity to R&D Chief, Aligning Incentives

Entera Bio Ltd. has granted 26,316 restricted stock units and 200,000 stock options to its Chief of R&D, Gregory Burshtein, following shareholder approval.

Summary

• Entera Bio Ltd. (ENTX) granted 26,316 Ordinary Shares, in the form of stock-settled restricted stock units (RSUs), to Gregory Burshtein, Chief of R&D, on July 16, 2025.
• The RSUs were granted at a price of $0 and were in lieu of the Reporting Person's 2024 annual cash bonus.
• These RSUs vest ratably on a quarterly basis over a one-year period, commencing on April 28, 2025.
• Additionally, 200,000 stock options were granted to Gregory Burshtein on July 16, 2025, with an exercise price of $2.28 per share.
• The stock options vest over a three-year period that began on April 28, 2025, with one-third vesting on the first anniversary and the remainder vesting ratably quarterly over the subsequent two years.
• Both the RSU and option grants were approved by the Company's Board of Directors on April 28, 2025, and subsequently by the Company's shareholders on July 16, 2025.
• Following these transactions, Gregory Burshtein beneficially owns 101,442 Ordinary Shares directly and 200,000 stock options directly.

Sentiment

Score: 8

Explanation: The grant of equity to a key R&D executive is a positive development, signaling commitment to retaining talent and aligning management incentives with shareholder interests. It's a standard practice that generally bodes well for long-term company stability and strategic execution.

Positives

• The equity grants to the Chief of R&D, Gregory Burshtein, serve to align his interests directly with those of the shareholders, incentivizing long-term performance and value creation.
• Granting equity in lieu of a cash bonus for 2024 demonstrates a commitment to conserving cash while still compensating a key executive.
• The vesting schedules for both RSUs (one year) and options (three years) promote retention of a critical R&D executive, which is vital for a biotechnology company.

Negatives

• The issuance of new shares and options could lead to a degree of dilution for existing shareholders, although this is a common practice for executive compensation.

Future Outlook

The grants include forward-looking vesting schedules: restricted stock units will vest ratably quarterly over one year from April 28, 2025, and stock options will vest over a three-year period from April 28, 2025, with one-third vesting on the first anniversary and the remainder vesting ratably quarterly over the subsequent two years.

Industry Context

Executive equity compensation, including restricted stock units and stock options, is a standard practice in the biotechnology and pharmaceutical industries. It is commonly used to attract, retain, and incentivize key scientific and management personnel, aligning their long-term interests with the company's success and shareholder value creation.

Comparison to Industry Standards

• The structure of granting both RSUs and stock options is a common approach in the biotech sector, balancing immediate value (RSUs) with long-term upside potential (options).
• The vesting periods (one year for RSUs, three years for options) are typical for executive compensation packages, designed to ensure retention and sustained performance.
• While specific compensation amounts vary widely based on company size, stage of development, and executive role, the mechanism of shareholder approval for significant equity grants is a standard corporate governance practice.

Corporate Governance

Related Party Transactions

• The grant of 26,316 restricted stock units and 200,000 stock options to Gregory Burshtein, the Chief of R&D, constitutes a related party transaction as he is an officer of the company.

Stakeholder Impact

• Shareholders: Potential for minor dilution due to new share issuance, but also benefit from enhanced alignment of executive incentives with long-term company performance.
• Employees (specifically Gregory Burshtein): Receives significant equity compensation, incentivizing continued dedication and performance, and serving as a retention mechanism.

Next Steps

• Continued vesting of 26,316 restricted stock units quarterly over a one-year period from April 28, 2025.
• Continued vesting of 200,000 stock options over a three-year period from April 28, 2025, with one-third vesting on the first anniversary and the remainder vesting ratably quarterly over the subsequent two years.

Key Dates

Keywords

Entera Bio Ltd., ENTX, SEC Form 4, Beneficial Ownership, Restricted Stock Units, Stock Options, Executive Compensation, Gregory Burshtein, Chief of R&D, Equity Grant, Shareholder Approval, Vesting Schedule